SALT LAKE CITY , Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics , Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its third quarter 2026 financial results on Thursday, November 12, 2026 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan , Chief Executive Officer and Daniel Bohrer , Executive Vice President of Finance and Accounting. The conference call and webcast will be available via: Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here Conference Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll) If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease. View original content to download multimedia: https://www.prnewswire.com/news-releases/co-diagnostics-announces-third-quarter-2026-earnings-release-date-and-webcast-302923340.html SOURCE Co-Diagnostics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.